Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

Plaque Psoriasis ◽

Fixed Combination ◽

Controlled Trials ◽

Phase 3 ◽

Two Phase ◽

Severe Plaque Psoriasis ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Abstract not available.

Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.3.supp.28 ◽

2019 ◽

Vol 3 ◽

pp. S28

Author(s):

Andrew F Alexis ◽

Paul S Yamauchi ◽

Tina Lin ◽

Gina Martin

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Controlled Trials ◽

Hispanic Population ◽

Phase 3 ◽

Two Phase ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Abstract not available.

Efficacy, safety and tolerability of a halobetasol 0.01%/tazarotene 0.045% fixed combination in the treatment of moderate-to-severe plaque psoriasis in a Hispanic population: Post hoc analysis of 2 phase III randomized controlled trials

10.1016/j.jaad.2019.06.745 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB202

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Phase Iii ◽

Controlled Trials ◽

Hispanic Population ◽

Severe Plaque Psoriasis ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Efficacy, safety and tolerability of a halobetasol 0.01%/tazarotene 0.045% fixed combination in the treatment of severe plaque psoriasis: Post hoc analysis of 2 phase III randomized controlled trials

10.1016/j.jaad.2019.06.746 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB202

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Phase Iii ◽

Controlled Trials ◽

Severe Plaque Psoriasis ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials

10.1016/j.jaad.2018.03.040 ◽

2018 ◽

Vol 79 (2) ◽

pp. 287-293 ◽

Cited By ~ 15

Author(s):

Linda Stein Gold ◽

Mark G. Lebwohl ◽

Jeffrey L. Sugarman ◽

David M. Pariser ◽

Tina Lin ◽

...

Keyword(s):

Plaque Psoriasis ◽

Fixed Combination ◽

Controlled Trials ◽

Phase 3 ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis ◽

Randomized Controlled

Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials

Pediatric Dermatology ◽

10.1111/pde.13723 ◽

2018 ◽

Vol 36 (1) ◽

pp. 89-99 ◽

Cited By ~ 10

Author(s):

Adelaide A. Hebert ◽

Dee Anna Glaser ◽

Lawrence Green ◽

William P. Werschler ◽

Douglass W. Forsha ◽

...

Keyword(s):

Controlled Trials ◽

Efficacy And Safety ◽

Axillary Hyperhidrosis ◽

Two Phase ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials

Pediatric Dermatology ◽

10.1111/pde.13877 ◽

2019 ◽

Vol 36 (3) ◽

pp. 424-424

Keyword(s):

Controlled Trials ◽

Efficacy And Safety ◽

Axillary Hyperhidrosis ◽

Two Phase ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Exposure-response analyses from a phase 2b and two phase 3 randomized controlled trials of tildrakizumab for the treatment of chronic plaque psoriasis

10.1016/j.jaad.2018.05.577 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB139

Keyword(s):

Plaque Psoriasis ◽

Controlled Trials ◽

Chronic Plaque Psoriasis ◽

Phase 3 ◽

Two Phase ◽

Randomized Controlled ◽

Exposure Response

Faculty Opinions recommendation of Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718010200.793476613 ◽

2013 ◽

Author(s):

Victoria Werth

Keyword(s):

Plaque Psoriasis ◽

Global Assessment ◽

Severity Index ◽

Biologic Agents ◽

Controlled Trials ◽

Physician Global Assessment ◽

Systematic Analysis ◽

Severe Plaque Psoriasis ◽

Randomized Controlled

Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

World Allergy Organization Journal ◽

10.1016/j.waojou.2020.100203 ◽

2020 ◽

Vol 13 (8) ◽

pp. 100203

Author(s):

David Muccino ◽

George Philip ◽

A.H. Morice ◽

S.S. Birring ◽

L. Mcgarvey ◽

...

Keyword(s):

Receptor Antagonist ◽

Chronic Cough ◽

Controlled Trials ◽

P2x3 Receptor ◽

Phase 3 ◽

Two Phase ◽

Randomized Controlled

P1-052: EFFICACY OF MEMANTINE ADDED TO CHOLINESTERASE INHIBITORS ON SIB BEHAVIORAL DOMAINS: POOLED POST HOC ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS IN PATIENTS WITH MODERATE TO SEVERE AD

Alzheimer s & Dementia ◽

10.1016/j.jalz.2018.06.054 ◽

2006 ◽

Vol 14 (7S_Part_5) ◽

pp. P287-P288

Author(s):

Frederick A. Schmitt ◽

George T. Grossberg ◽

Pierre N. Tariot ◽

Suzanne Hendrix ◽

Noel Ellison ◽

...

Keyword(s):

Cholinesterase Inhibitors ◽

Controlled Trials ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Post Hoc ◽

Behavioral Domains